Web This site Trusted
5 result(s) for “date 2020 site www newswire ca site tradigitalir com site:tradigitalir.com” · 628 ms
Scope: Nishi’s own index (our crawl + Common Crawl) — not the whole live web. Some sites block all automated crawlers (anti-bot walls), so their pages may be absent here even though we never filter lawful content.
Freshness: no result on this page carries a fetch time yet (indexed before the fetch epoch was stored beside the doc)
com
SOURCE: Aspire Biopharma Holdings, Inc
from the top result below
https://tradigitalir.com/aspire-biopharma-holdings-inc-nasdaqasbp-commences-initial-production-of-its-pre-workout-performance-supplement/
com
SOURCE: Aspire Biopharma Holdings, Inc
https://tradigitalir.com/aspire-biopharma-holdings-inc-nasdaqasbp-contract-manufacturer-glatt-air-techniques-inc-has-completed-its-first-good-manufacturing-practice-gmp-clinical-batch-of-pharmace/
study in April 2025
Aspire intends to request “fast track” approval on FDA application for its high dose aspirin product
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Aspire Biopharma Holdings, Inc
https://tradigitalir.com/correlate-energy-otc-cipi-converts-nearly-8-million-of-debt-into-preferred-equity-strengthening-financial-position-and-converting-most-of-its-debt-into-equity/
com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
https://tradigitalir.com/american-rebel-holdings-inc-nasdaq-areb-announces-experienced-outdoor-industry-executive-thomas-mihalek-as-the-new-chief-executive-officer-of-provo-utah-based-champion-safe/
com), announces the appointment of Thomas Mihalek as CEO of Champion Safe (www
https://tradigitalir.com/atai-life-sciences-nasdaq-atai-presents-pharmacodynamic-data-on-grx-917-in-a-late-breaking-poster-presentation-at-the-2023-sobp-annual-meeting/
side effects associated with benzodiazepines
NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data on GRX-917, a deuterated